Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.73 |
| ▸ | EGFR | P00533 | 13/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.71 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568971 | 0.89 | ERBB2 (0.76) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL9973619 | 0.89 | ERBB2 (0.73) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL30125866 | 0.89 | ERBB2 (0.73) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL2989878 | 0.89 | ERBB2 (0.73) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL17845956 | 0.89 | ERBB2 (0.73) | ERBB2EGFRLCKERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL17845945 | 0.89 | ERBB2 (0.72) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL27751265 | 0.89 | ERBB2 (0.72) | ERBB2EGFRLCKERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL29793455 | 0.89 | ERBB2 (0.72) | ERBB2EGFRLCKERBB3ERBB4 | |
| SCHEMBL5497053 | 0.88 | ERBB2 (0.66) | ERBB2EGFRLCKERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL11893854 | 0.88 | ERBB2 (0.71) | ERBB2EGFRLCKERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885LCK 29/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885LCK 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.